Arcus Biosciences, Inc.

Valuation Analysis

About the Company

Arcus Biosciences, Inc. en bref

Arcus Biosciences, Inc. (RCUS) is currently trading at 21,14 € with a market capitalization of 2,7 Md €. The 52-week range spans from 6,90 € to 25,04 €; the current price is 15.6% below the yearly high. Year-over-year revenue growth stands at -39.3%.

💰 Dividende

Arcus Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

12 analystes évaluent Arcus Biosciences, Inc. (RCUS) au consensus : Achat Fort. L'objectif de cours moyen est de 31,17 €, soit un potentiel de +47.42% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 19,18 € à 40,97 €.

Arcus Biosciences, Inc. : la thèse d'investissement en détail

Arcus Biosciences, Inc. (RCUS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 47.42% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -39.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 15.32% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 47.42% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (15.32%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Arcus Biosciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.